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Abstract Mapping between non-preference- and prefer-
ence-based health-related quality-of-life instruments has
become a common technique for estimating health state
utility values for use in economic evaluations. Despite the
increased use of mapped health state utility estimates in
health technology assessment and economic evaluation, the
methods for deriving them have not been fully justified.
Recent guidelines aim to standardise reporting of the
methods used to map between instruments but do not
address fundamental concerns in the underlying conceptual
model. Current mapping methods ignore the important
conceptual issues that arise when extrapolating results from
potentially unrelated measures. At the crux of the mapping
problem is a question of validity; because one instrument
can be used to predict the scores on another, does this mean
that the same preference for health is being measured in
actual and estimated health state utility values? We refer to
this as conceptual validity. This paper aims to (1) explain
the idea of conceptual validity in mapping and its impli-
cations; (2) consider the consequences of poor conceptual
validity when mapping for decision making in the context
of healthcare resource allocation; and (3) offer some
preliminary suggestions for improving conceptual validity
in mapping.
Key Points for Decision Makers
Estimating health state utility values using mapping
algorithms is becoming commonplace.
The conceptual basis of this process is poorly
developed; that one instrument can be used to predict
the scores on another does not mean that the same
preference for health is being measured.
Decision validity is contingent on health state utility
values meaning what is claimed.
1 Introduction
Mapping (sometimes called ‘cross-walking’) has become a
common technique for estimating health state utility values
for use in economic evaluations [1]. It typically refers to
the process of statistically estimating health state utility
values for use in an economic evaluation by predicting
results for a target preference-based measure (e.g. the EQ-
5D [2]) from data collected using a non-preference-based
measure (often a condition-specific measure) [3]. The
publication and use of mapping algorithms has increased
significantly since, in its methodology guidelines for
technology appraisals, the National Institute for Health and
Care Excellence recommended the use of mapped health
state utility estimates when data collected directly from
patients are not available [4, 5].
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A large number of non-preference-based instruments
have been, and continue to be, developed for use in health
research. In particular, condition-specific, non-preference-
based measures represent a rich source of information
about the quality of life of studied populations. However,
because no set of preference weights exist for these mea-
sures, they have limited use in allocating scarce healthcare
resources, not only between treatments for the same or
similar conditions but also especially across different areas
of healthcare. The development of a statistical model that
enables researchers to translate information gained from a
non-preference-based instrument into health state utility
scores for use in economic evaluations has use in a variety
of scenarios. For instance, such mapped estimates allow
data to be used to evaluate technologies where a condition-
specific measure of quality of life has been collected during
an evaluation, but not a preference-based measure. Yet
despite the increased level of interest in mapping [1, 3, 6]
and the publication of reporting guidelines [7], the validity
of using mapping to estimate utility values has not been
fully addressed.
McCabe et al. [8] identified multiple areas of concern in
the development of mapping algorithms. In particular, they
argued that it cannot be assumed that utility values pre-
dicted by a mapping algorithm are representative of
directly measured utility values. Therefore, at the crux of
the mapping problem is a question of validity. Just because
one instrument can be used to predict the scores on another,
does this mean that the same preference for health is being
measured in actual and estimated health state utility val-
ues? In this article, we describe this as the problem of
‘conceptual validity’ [9]. We distinguish conceptual
validity from the related concept of content validity. The
latter is related to how well a single instrument reflects the
underlying constructs being measured. On the other hand,
conceptual validity relates to the degree to which the
content of two different instruments reflect one another
when used for mapping.
This paper aims to (1) explain the idea of conceptual
validity in mapping and its implications; (2) consider the
consequences of poor conceptual validity when mapping
for decision making in the context of healthcare resource
allocation; and (3) offer some preliminary suggestions for
improving conceptual validity in mapping.
2 Mapping and Conceptual Validity
Current methods of mapping have focused on the mean or
average accuracy with which the results of one instrument
can be predicted based on responses to a second instrument
[3, 10]. Mapping techniques have become increasingly
statistically sophisticated [11, 12] and accepted approaches
for demonstrating validity are broadly statistical [4]. The
final function is determined based on performance
according to some error measurement statistic, typically
either mean absolute error (MAE) or root mean squared
error (RMSE). By finding a model that, on average, best
estimates actual scores, it is generally assumed that this is
therefore the model that leads to the greatest reduction in
uncertainty in the final mapped estimates.
2.1 Transmutation of Data in the Mapping Process
Nonetheless, against this statistical backdrop, the concep-
tual context of what happens when mapping occurs seems
to have been lost, as has consideration of what the mapped
estimates mean. It is not enough to be able to say that the
scores of Measure A are highly predictive of scores for
Measure B if it cannot be said with any confidence that A
and B are measuring the same thing. Estimating a reliable
mapping function using an appropriate statistical method is
a necessary condition for a mapping process to be con-
sidered valid, but it is of itself not sufficient.
Preference-based generic instruments such as the EQ-
5D [2] and the SF-6D [13, 14] have been developed to give
a broad picture of overall health but, as a result, have been
considered insensitive to small changes in specific aspects
of health. Non-preference-based measures of quality of life
can be mapped to preference-based measures to provide
estimates of utility scores. These may cover broadly similar
domains. In some cases, they may be too lengthy for the
development of a preference set (e.g. the WHOQOL [15]).
In the event that the non-preference-based measure is itself
brief, it may be subject to the same criticism as brief
preference-based measures in that it may not be sensitive to
change in the study population.
To address concerns around the sensitivity to change of
generic instruments, condition-specific instruments are
often used. Condition-specific instruments, such as the
Asthma Quality of Life Questionnaire (AQLQ) [16],
measure different domains of health than generic instru-
ments, or measure the same domains but at a different level
of detail. These measures are often designed to be more
sensitive to changes in health that are specifically due to
that condition of interest, although they may not be good
indicators of overall health or preferences for health [17]. It
is, in part, these differing objectives in instrument design
that may lead to a lack of conceptual validity in mapped
estimates.
Mapping methods also often include consideration of
the clinical and demographic overlap between the estima-
tion sample and the target sample to provide more robust
results. However, including covariates in mapping func-
tions can reduce their functionality. Where covariates are
an important part of the prediction function, the end user in
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turn needs to have details of the same covariate variables
for their study participants in order to use the algorithm. As
such, covariates are not always included in mapping
functions. In addition, the nature of the covariates in the
estimation and target samples does not affect the extent to
which the two instruments are measuring the same
construct.
2.2 Changing Tin into Gold?
Conceptual validity is important to consider when assess-
ing the degree to which the source and target instruments
are measuring the same domains of health. No two
instruments will cover the exact same domains in the exact
same fashion, but it is important to consider the degree of
conceptual coherence between the source and target data.
Where there is little overlap between the constructs of
health being measured, mapping functions are unlikely to
be valid [18]. Consider the EQ-5D-3L [2], the most com-
monly used preference-based target instrument in mapping
studies [1, 3]. The EQ-5D-3L assesses five domains of
health: mobility, self-care, usual activities, pain/discomfort
and anxiety/depression. Other instruments, typically mea-
suring different health domains, are often mapped to the
EQ-5D preference set. For example the AQLQ [16] mea-
sures just four domains of health considered to be specif-
ically relevant to patients with asthma: symptoms, activity
limitation, emotional function and environmental stimuli.
While there is some overlap with the EQ-5D, it is clear that
the two instruments do not measure exactly the same
aspects of health. As utility values derived from the EQ-5D
have an upper and lower limit, accounting for the infor-
mation content in the AQLQ implicitly means that greater
preference will be given to the respiratory domain at the
expense of other domains; however, it is not currently
possible to quantify the extent to which this occurs.
Many studies use such condition-specific measures as
the source instrument when mapping to a preference-based
generic measure [1]. Condition-specific measures are often
narrower or more focussed in scope (by design) than
generic preference-based instruments, meaning that more
information may be collected, but pertaining to a narrower
set of domains of health. This additional information will
be lost when mapping between instruments, and, more
importantly, potentially relevant information will be mis-
sed relating to those domains of the preference-based
instrument that are not captured in the condition-specific
measure. This also has the negative effect of not clearly
accounting for potential interaction effects in the domains
being measured in mapped estimates, which amounts to an
unaccounted loss of information.
It can be argued that where an algorithm has a sufficient
prediction accuracy, use of a mapping algorithm to
estimate utility values should be based on whether the
algorithm will consistently reflect the relationship between
the instruments in an external population. This would
reflect a high degree of external validity and could provide
sufficient justification for use of the algorithm. However,
measures of error in the prediction algorithm (MAE,
RMSE) do not tell us what information comprises these
estimates and therefore, for example, how they are likely to
perform in relation to treatment effects. If one set of EQ-
5D mapped values are estimated from scores on a walking
scale and another set of EQ-5D mapped values are esti-
mated from scores on a fatigue scale, using the mapped
values in a cost-effectiveness analysis is likely to result in
different estimates of cost effectiveness if the intervention
focuses on improving mobility or improving fatigue. This
could be tested empirically.
In support of mapping, it can also be argued that the
mapped estimates reduce variation around the mean esti-
mate compared with directly observed values [18]; how-
ever, this is misleading. First, it does not address the
content problem, i.e. that the source and target instruments
are measuring similar constructs of health, and, second, it
says nothing about what information is lost during the
mapping.
2.3 Transmuting Lead to Gold?
This loss of information is only likely to be exacerbated
when mapping from a clinical measure to estimate health
state utility values (e.g. [19–21]) as is allowable under
National Institute for Health and Care Excellence (NICE)
guidance, given that an adequate mapping function can be
demonstrated and validated [4]. Clinical indicators capture
particular aspects of health status and do not necessarily
capture important changes to health-related quality-of-life
(HRQoL) that may occur as a result of treatment. For
example, an improvement in mobility that enables some-
one to be able to walk upstairs may have little impact on
their HRQoL if they live in a bungalow, or a small
improvement in pain may have a significant impact on an
individual’s self-reported HRQoL [17]. Using clinical
indicators as the source data to map to a preference-based
measure therefore limits the amount of information that can
be translated into health state utility scores. In effect, this
fails to overcome the principle objection to using clinical
indicators, which is that comparisons cannot be made
between interventions for different conditions because
preferences for health states cannot be known from clinical
indicators alone. A simple mapped estimate of preferences
does not address this problem. Such mapped estimates will
reflect only those domains directly relevant to the indicator
selected, without capturing broader information about
HRQoL. Because mapped estimates based solely on
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clinical outcome indicators cannot distinguish which
aspects of HRQoL are being captured in the final estimate,
it is unlikely that clinical indicators can ever be a valid
source for mapped estimates.
2.4 Turning Silver into Gold?
A third key problem relating to conceptual validity exists
where the same domains of health are being measured.
This arises from different ways of measuring the severity
of each problem in a given domain of health, including
those cases where there is a clear overlap between instru-
ments in terms of the domains they assess. For example,
the SF-12 [13, 14] and the EQ-5D both include dimensions
regarding mental health (in the SF-12 this is the mental
health component score, and in the EQ-5D this is the
anxiety/depression dimension), but they give different
amounts of information. The SF-12 includes six questions
that relate to mental health, compared with just one ques-
tion in the EQ-5D. Mapping from the SF-12 to the EQ-5D
will inevitably lead to a loss of information pertaining to
this domain.
When a non-preference-based measure of health out-
come is mapped to a preference-based measure, it is not
known what domains of health or HRQoL are retained in
the resulting estimates and those aspects that are lost. The
nature of the preference for health that is lost in mapped
estimates is unknown, as is the nature of the preference for
health that is retained. This raises questions about the
validity of mapped estimates for use in healthcare decision
making, as described in Sect. 4.2.
The problem of conceptual validity, or even the loss of
information during the mapping process has not been fully
addressed in the literature. While the inclusion of a ques-
tion concerning conceptual overlap in the recent mapping
reporting standard [7] should increase the attention this
issue receives, to date only a very small number of studies
e.g. [22–24] have explicitly recognised the problem.
3 Potential Consequences of Poor Conceptual
Validity When Mapping
Different aspects of HRQoL will be included in mapped
estimates from different condition-specific measures due to
the differing conceptual overlap between the descriptive
systems of pairs of instruments. This may result in sys-
tematic biases in the preferences for health that are lost and
retained when mapped estimates are derived.
For example, the Multiple Sclerosis Impact Scale-29
(MSIS-29) [25, 26] is a patient-reported outcome measure
that assesses the impact of multiple sclerosis (MS) on
people’s HRQoL. It has two subscales that assess the
impact of MS on physical functioning and psychological
functioning, but does not include questions relating to
mobility. The Multiple Sclerosis Walking Scale-12
(MSWS-12) [27] is also a patient-reported outcome mea-
sure that specifically assesses the impact of MS on people’s
mobility. Mapping from scores on the MSIS-29 to the EQ-
5D will result in EQ-5D estimates that exclude, to a great
extent, aspects of HRQoL pertaining to mobility, while
mapping from scores on the MSWS-12 to the EQ-5D will
result in EQ-5D estimates largely dominated by the impact
of MS on mobility. The extent to which these mapped
estimates might then be considered equivalent is highly
questionable.
There is a focus in the literature on the effect of adding
dimensional information when deriving health state utility
values [28], however, there has been little, if any, consid-
eration of the impact of losing dimensional information, as
is the case with mapping. When mapping, content that is
not included in the descriptive systems of both of the
measures, e.g. a condition-specific measure and the EQ-5D,
will be lost. In addition, when mapping, the salience of
some of the dimensions may be altered, as illustrated in the
example above with the MSIS-29 and MSWS-12. This
could mean that the remaining health states may have been
valued differently by the general population, i.e. the pref-
erence-based measure will have been valued based on all
the included domains, but, in the process of mapping, much
of this information may be lost, and the remaining health
states may have been valued differently. As such, mapped
estimates may not capture the genuine preferences of the
general population.
4 Improving the Conceptual Validity of Mapping
Algorithms
The assessment and treatment of conceptual validity and
information loss in mapping is at an embryonic stage. The
approaches to dealing with validity in mapping have
focused almost entirely on the statistical predictive nature
of mapping functions. This leaves a gap in our under-
standing of the mapping process as predictive accuracy can
only tell us how closely scores are related, not whether they
are assessing the same preferences for health. The fol-
lowing are preliminary suggestions for how conceptual
validity might be assessed in the mapping process.
4.1 Response Mapping
Mapping is conducted in two main ways. The most com-
mon form involves scores on the starting measure being
regressed directly onto health state utility values (e.g. EQ-
5D index scores). The second approach uses a two-stage
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process. Scores on the starting measure are firstly regressed
onto responses on the health status measure (e.g. EQ-5D
dimension scores), and health state utility values, usually
from general population samples, are thereafter assigned to
them.
This latter approach, termed response mapping [29],
appears to offer no clear statistical advantage over mapping
directly to health state utility values. It seems to work
better at predicting individual scores and score ranges, but
indications are that it generates larger errors across groups
[30–35]. However, as Parkin et al. [36] describe, using EQ-
5D index data, which are derived from people’s reports of
health status to which health state utility values from the
general population are applied, means that any statistical
analysis with the EQ-5D index is affected not just by
variations in scores due to the sample but also by variations
in scores due to the values given by the general population.
When mapping, this serves to add unidentified complexity
to the relationship between scores on the starting measure
and EQ-5D index scores. As such, it may be argued that
response mapping offers greater conceptual clarity
regarding the relationship between measures, what is being
mapped to what, and what is lost and retained in the
mapping procedure. Also, unless response mapping is used,
the process of mapping does not directly relate conceptual
dimensions on the starting measure to conceptual dimen-
sions on the target measure. Rather, scores on conceptual
dimensions on the starting measure are related to general
population preferences for degrees of the conceptual
dimensions on the target measure.
4.2 Decision Validity
Without considering conceptual validity, it is not possible
to assess whether resource allocation decisions based on
such estimates are valid. The validity of an individual
instrument has traditionally been measured according to a
set of established criteria and, in particular, four key cri-
teria: face, content, criterion and construct validity [37].
This differs from how validity needs to be assessed as part
of the development of mapping functions, where it will be
necessary to establish a method for assessing the validity of
the process of conversion from one instrument to another.
This may use the established definitions of validity but
must also consider if there are other criteria by which this
function can be judged.
The concept of decision validity [38] may offer such an
additional criterion. Decision validity refers to the degree
of certainty that the decision made is the correct one, given
the available information. Decision validity then is the
ultimate arbiter for any mapping function; there is a direct
relationship between the robustness of mapped utility
estimates and the validity of any decision informed by
those estimates. Thus, if the conceptual uncertainty sur-
rounding a decision falls within an acceptable range given
the currently available information, it can be concluded
that the decision is valid and therefore that the mapping
function is valid.
For establishing conceptual decision validity, there must
be a prima facie case that a function that maps between any
two given instruments satisfies the set of conditions out-
lined below. Analysts should assess the following:
(a) the degree to which the two instruments measure the
same or similar concepts (face validity);
(b) the degree to which the two instruments measure the
same hypothetical constructs (construct validity);
(c) the extent that scores from the source instrument
correlate with those from the target (or gold standard)
instrument (criterion validity).
If the analyst is satisfied by the expected degree of
conceptual coherence between the two instruments, there is
a prima facie case that a mapping function may potentially
lead to a valid decision. There is currently no specific
guidance on what degree of conceptual overlap is required
to proceed with the production of a mapping algorithm.
Further research is needed to inform guidance on appro-
priate methods for assessing conceptual overlap and the
cut-offs at which a lack of coherence is liable to result in
erroneous resource allocation decisions (compared with the
application of directly derived health utility values).
This is, of itself, not sufficient. A method is needed to be
able to establish the nature of what is lost when a mapping
algorithm is used, not just how much is lost. For example, if
aspects of HRQoL pertaining to mobility are lost in the
mapping process because there is no assessment relating to
mobility in the starting measure, and therefore no overlap
on this domain between the starting measure and the target
measure, it seems important to know that the health state
utility value estimates will contain very little information
relating to mobility and preferences for mobility-affected
health states. Assessing what content is retained and what
content is lost in a mapping algorithm might be addressed
by starting with a conceptual map of the construct being
mapped from (e.g. on the basis of good-quality qualitative
research). For example, if wishing to map from the Fatigue
Severity Scale to the EQ-5D, the conceptual overlap
assessment could begin by setting out a framework of the
areas of impact of fatigue on people’s lives. The descrip-
tive content of the preference-based measure being mapped
to, e.g. the EQ-5D, could then be assessed on an item-by-
item basis in relation to this framework to identify areas of
overlap and difference.
Analysts are encouraged to consider the conceptual
validity of mapping in relation to their resource allocation
decision, to consider what criteria might be used to assess
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conceptual validity, to consider the possible consequences
of using mapping algorithms that are not ‘conceptually
valid’, and to sometimes not map because it is not con-
ceptually valid to do so.
5 Conclusions
The conclusions drawn in this paper are at odds with NICE
guidance suggesting the use of mapped estimates in health
technology appraisals [4, 5]. The acceptance of mapping
before key conceptual aspects of the methodology are
established may lead to a series of unintended and
unwelcome consequences; treatments may erroneously be
approved or rejected or investment may be made on the
basis of poor information about the quality of life of the
intended population. As is shown in this article, current
methods used for mapping are not known to be conceptu-
ally robust. Any allocation decisions taken based on current
mapped estimates, even if by chance they are the ‘correct’
decisions, can currently only be described as valid in a
post hoc manner; however, waiting until the decision has
been implemented to determine whether it is a valid
decision does not address the original problem. Until the
methodology exists for determining the validity of deci-
sions based on mapped estimates, mapping should not be
used for estimating preferences, and the best option
remains valuation through the use of an established pref-
erence-based instrument or valuation technique. We agree
with the conclusions of McCabe et al. [8] that, in its current
guise, there is a significant risk that mapping may be
harmful to population health, and recommend that mapping
research now focuses on developing criteria for when it is
and is not conceptually valid to derive a mapping
algorithm.
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